Bioretec Q2'25: Slower sales development than expected

Bioretec's weak Q2 earnings were a disappointment compared to expectations. The company's revenue and gross margin % decreased sharply, and the simultaneous increase in operational costs doubled the operating loss. Bioretec's interim CEO Sarah Hubar-Fisher provides more details in an interview with analyst Antti Siltanen.

Topics
00:00 Introduction
00:13 Q2 summary
02:18 Negative revenue impact of ended Spartan Medical distribution deal
03:06 Weak performance in Europe and the United States
05:46 Status of country-specific processes in terms of RemeOs sales 
06:55 Expectations for the rest of the year
08:48 Reasons to focus more on sales agent model
09:43 Main bottlenecks and obstacles for increasing sales
11:11 Indication expansion in US
12:09 RemeOs's sales outlook in the United States
13:11 Sales agent model
14:50 Opex level
15:48 Increased working capital level
16:50 R&D pipeline
18:11 Development of single-use tools
19:50 Reimbursements
21:00 Learnings in RemeOs’s commercialization
22:16 Final words